Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Delta 9 Cannabis Inc DLTNF

Delta 9 Cannabis Inc. is a Canada-based vertically integrated cannabis company. The Company operates through three segments: Wholesale Cannabis, Retail Cannabis and Merchandise and Devices, and Business to Business. The Company sells cannabis products through its wholesale and retail sales channels and sells its cannabis growing pods to other businesses. Its cannabis products include dried cannabis and pre-rolled joints. Its edibles and vapes include vape pens and concentrates, edibles, and drinkables. The Company, through its wholly owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis products and operates a 95,000-square-foot Health Canada licensed production facility in Winnipeg, Manitoba, Canada. It also owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand. It is focused on producing and selling cannabis oils, extracts, and derivative products.


GREY:DLTNF - Post by User

Post by Oceanison Jun 29, 2021 7:53am
222 Views
Post# 33464978

New CHAIR Nitin Kaushal: Credentials!

New CHAIR Nitin Kaushal: Credentials! Long time d9 Director makes the move to 'Chair' and is seen as a very strong sign by analysts that their B2B into the US is on fire and that there future looks bright/well-seated for continued growth. 
  • Managing Director in the Deals practice at PwC
  • *More than 25 years experience in financial investing, life sciences, consumer healthcare, healthcare services and medical device industries 
  • *Sat on the board of numerous pharmaceutical and healthcare companies, and held senior roles in investment banking, venture capital and consulting firms
  •  *Ranked as the top Healthcare Investment Banker in 2008/2009 by Brendan Wood International
D9 potential looking very very good and I would not be surprised in the slightest to see them beat their guidance of 15.5 million to 17.5 on August 16th/Before Markets Open.

They've increased their annual revenue from 600k/2017 to over 50 million in annual revenue in 3 short years /2020 and, are showing no signs of slowing down whatsover...to the contrary.
glta 
<< Previous
Bullboard Posts
Next >>